Skip to main content
Clinical Trials/JPRN-UMIN000040623
JPRN-UMIN000040623
Completed
未知

The exploratory observational study on the safety of Dormolol combination ophthalmic solution wakamoto under medical practice. - The observational study on the safety of Dormolol combination ophthalmic solution wakamoto.

Wakamoto Pharmaceutical Co., Ltd.0 sites98 target enrollmentJune 3, 2020

Overview

Phase
未知
Intervention
Not specified
Conditions
Glaucoma Ocular hypertension
Sponsor
Wakamoto Pharmaceutical Co., Ltd.
Enrollment
98
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

ot listed

Registry
who.int
Start Date
June 3, 2020
End Date
September 30, 2020
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not applicable

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
A study to see the effect of 2 chemotherapy drugs- Cyclophosphamide and Methotrexate when given in a low dose form in women having Metastatic Triple Negative Breast cancerHealth Condition 1: null- Women with metastatic triple negative breast cancer
CTRI/2015/07/006016Jehangir Clinical Development centre Pvt ltd40
Completed
Not Applicable
The prospective exploratory study of safety and efficacy on the patients post-penetrating keratoplasty of topical tacrolimus 0.1%.Penetrating keratoplasty (PKP)
JPRN-UMIN000029669Tokyo Dental Collage Ichikawa General Hospital30
Active, not recruiting
Phase 2
Physician-initiated clinical trial in patients with 5-aminolevulinic acid-induced ATR-X syndrome.ATR-X syndromeinfant, intellectual disability, epigenetics, guanine quadruplexD008607
JPRN-jRCT2051220062Wada Takahito5
Recruiting
Phase 2
SOBERANA PEDIATRIA CLINICA 1COVID-19SARS-CoV2Disease PreventionCoronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusPediatrics
RPCEC00000384Instituto Finlay de Vacunas (IFV)425
Not yet recruiting
Not Applicable
An observational study investigating the safety, tolerability and health outcomes of cannabinoid therapy prescribed to eligible patients for management of recognized chronic conditionsAny recognized condition for which medicinal cannabis could be prescribed forChronic PainAnxietyInsomniaPost-traumatic stress disorderDementiaParkinson's disease/TremorSeizure management/EpilepsyNeuropathic painMood DisorderAutismInflammatory bowel disease/Irritable bowel syndromeChemotherapy-induced nausea and vomitingAnaesthesiology - Pain managementMental Health - AnxietyNeurological - EpilepsyMental Health - Other mental health disordersNeurological - Parkinson's diseaseNeurological - Other neurological disordersCancer - Any cancer
ACTRN12623000149662Cloud Medical PTY LTD2,000